BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 20726683)

  • 1. Trends in treatment strategies and the usage of different disease-modifying anti-rheumatic drugs in early rheumatoid arthritis in Finland. Results from a nationwide register in 2000-2007.
    Rantalaiho V; Kautiainen H; Virta L; Korpela M; Möttönen T; Puolakka K
    Scand J Rheumatol; 2011 Jan; 40(1):16-21. PubMed ID: 20726683
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of early rheumatoid arthritis in developing countries. Biologics or disease-modifying anti-rheumatic drugs?
    Yen JH
    Biomed Pharmacother; 2006 Dec; 60(10):688-92. PubMed ID: 17049202
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A marked decline in the incidence of renal replacement therapy for amyloidosis associated with inflammatory rheumatic diseases - data from nationwide registries in Finland.
    Immonen K; Finne P; Grönhagen-Riska C; Pettersson T; Klaukka T; Kautiainen H; Hakala M
    Amyloid; 2011 Mar; 18(1):25-8. PubMed ID: 21284495
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Decline in work disability caused by early rheumatoid arthritis: results from a nationwide Finnish register, 2000-8.
    Rantalaiho VM; Kautiainen H; Järvenpää S; Virta L; Pohjolainen T; Korpela M; Möttönen T; Puolakka K
    Ann Rheum Dis; 2013 May; 72(5):672-7. PubMed ID: 22679306
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug management of early rheumatoid arthritis - 2008.
    Sokka T; Mäkinen H
    Best Pract Res Clin Rheumatol; 2009 Feb; 23(1):93-102. PubMed ID: 19233049
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real-world utilization of DMARDs and biologics in rheumatoid arthritis: the RADIUS (Rheumatoid Arthritis Disease-Modifying Anti-Rheumatic Drug Intervention and Utilization Study) study.
    Gibofsky A; Palmer WR; Goldman JA; Lautzenheiser RL; Markenson JA; Weaver A; Schiff MH; Keystone EC; Paulus HE; Harrison MJ; Whitmore JB; Leff JA
    Curr Med Res Opin; 2006 Jan; 22(1):169-83. PubMed ID: 16393443
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A more active treatment has profound effects on the health status of rheumatoid arthritis (RA) patients: results from a population-based RA register in Malmö, Sweden, 1997-2005.
    Söderlin MK; Lindroth Y; Turesson C; Jacobsson LT
    Scand J Rheumatol; 2010 May; 39(3):206-11. PubMed ID: 20001765
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rituximab therapy in patients with rheumatoid arthritis refractory or with contraindication to anti-tumour necrosis factor drugs: real-life experience in Finnish patients.
    Valleala H; Korpela M; Möttönen T; Hienonen-Kempas T; Kauppi M; Hannonen P; Leirisalo-Repo M
    Scand J Rheumatol; 2009; 38(5):323-7. PubMed ID: 19585384
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register.
    Hyrich KL; Watson KD; Silman AJ; Symmons DP;
    Rheumatology (Oxford); 2006 Dec; 45(12):1558-65. PubMed ID: 16705046
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nationwide prevalence of rheumatoid arthritis and penetration of disease-modifying drugs in Sweden.
    Neovius M; Simard JF; Askling J;
    Ann Rheum Dis; 2011 Apr; 70(4):624-9. PubMed ID: 21149495
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Trends in disease modifying antirheumatic drug prescription in early rheumatoid arthritis are influenced more by hospital setting than patient or disease characteristics.
    Carli C; Ehlin AG; Klareskog L; Lindblad S; Montgomery SM
    Ann Rheum Dis; 2006 Aug; 65(8):1102-5. PubMed ID: 16322085
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Patients with stable long-standing rheumatoid arthritis continue to deteriorate despite intensified treatment with traditional disease modifying anti-rheumatic drugs--results of the British Rheumatoid Outcome Study Group randomized controlled clinical trial.
    Symmons D; Tricker K; Harrison M; Roberts C; Davis M; Dawes P; Hassell A; Knight S; Mulherin D; Scott DL;
    Rheumatology (Oxford); 2006 May; 45(5):558-65. PubMed ID: 16263778
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Do biologic drugs affect the need for and outcome of joint replacements in patients with rheumatoid arthritis? A register-based study.
    Aaltonen KJ; Virkki LM; Jämsen E; Sokka T; Konttinen YT; Peltomaa R; Tuompo R; Yli-Kerttula T; Kortelainen S; Ahokas-Tuohinto P; Blom M; Nordström DC
    Semin Arthritis Rheum; 2013 Aug; 43(1):55-62. PubMed ID: 23481417
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gaps in care for rheumatoid arthritis: a population study.
    Lacaille D; Anis AH; Guh DP; Esdaile JM
    Arthritis Rheum; 2005 Apr; 53(2):241-8. PubMed ID: 15818655
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Initial disease modifying antirheumatic drugs and prednisolone prescriptions for patients with rheumatoid arthritis: a 15-year study.
    Osiri M; Akkasilpa S; Deesomchok U
    J Med Assoc Thai; 2000 Mar; 83(3):217-24. PubMed ID: 10808674
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Disease modifying anti-rheumatic drugs (DMARDs) in rheumatoid disease.
    Subhash C; Agarwal AK; Rewari BB; Sangla KS; Vijay A
    J Assoc Physicians India; 1995 Mar; 43(3):232-3. PubMed ID: 11256928
    [No Abstract]   [Full Text] [Related]  

  • 17. Contemporary use of disease-modifying drugs in the management of patients with early rheumatoid arthritis in Norway.
    Nikolaisen C; Kvien TK; Mikkelsen K; Kaufmann C; Rødevand E; Nossent JC
    Scand J Rheumatol; 2009; 38(4):240-5. PubMed ID: 19229766
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Trends in medication and health-related quality of life in a population-based rheumatoid arthritis register in Malmo, Sweden.
    Söderlin MK; Lindroth Y; Jacobsson LT
    Rheumatology (Oxford); 2007 Aug; 46(8):1355-8. PubMed ID: 17567634
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of initial aggressive drug treatment with a combination of disease-modifying antirheumatic drugs on the development of work disability in early rheumatoid arthritis: a five-year randomized followup trial.
    Puolakka K; Kautiainen H; Möttönen T; Hannonen P; Korpela M; Julkunen H; Luukkainen R; Vuori K; Paimela L; Blåfield H; Hakala M; Leirisalo-Repo M
    Arthritis Rheum; 2004 Jan; 50(1):55-62. PubMed ID: 14730599
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Conventional disease-modifying antirheumatic drugs in early arthritis.
    Sokka T; Hannonen P; Möttönen T
    Rheum Dis Clin North Am; 2005 Nov; 31(4):729-44. PubMed ID: 16287594
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.